HLB Life Science Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
August 11, 2023 at 03:43 am EDT
Share
HLB Life Science Co., Ltd. reported earnings results for the second quarter and six months ended June 30, 2023. For the second quarter, the company reported sales was KRW 21,429.51 million compared to KRW 15,868.22 million a year ago. Net loss was KRW 9,780.28 million compared to net income of KRW 6,594.74 million a year ago. Basic loss per share from continuing operations was KRW 96 compared to basic earnings per share from continuing operations of KRW 65.6082 a year ago. Diluted loss per share from continuing operations was KRW 96 compared to diluted earnings per share from continuing operations of KRW 65.6082 a year ago. Basic loss per share was KRW 96 compared to basic earnings per share of KRW 69 a year ago.
For the six months, sales was KRW 869.6 million compared to KRW 200.39 million a year ago. Net income was KRW 3,878.98 million compared to net loss of KRW 3,772.76 million a year ago. Basic earnings per share from continuing operations was KRW 38 compared to basic loss per share from continuing operations of KRW 38.0337 a year ago. Diluted earnings per share from continuing operations was KRW 38 compared to diluted loss per share from continuing operations of KRW 38.0337 a year ago. Basic earnings per share was KRW 38 compared to basic loss per share of KRW 40 a year ago.
HLB Life Science Co., Ltd. is a Korea-based company mainly engaged in the sale of pharmaceuticals. Along with subsidiaries, the Company operates its business through four segments. The Pharmaceutical Distribution segment is involved in the sale of pharmaceuticals and raw materials through SHINWHAADVANCE.CO.LTD. The Energy Business segment is engaged in energy service company (ESCO) business. It is equipped with equipments, assets and technical personnel to engage in energy saving investment business. The Bio Development segment is engaged in the development of extracorporeal circulation type bio space, hepatocyte treatment agents and hemostatic agents. The main products include anticancer drugs such as Tegatrabetan and Seclidemstat. The Other Business segment is involved in the investment of small business start-ups and venture businesses, as well as manufacturing and sale of light emitting diode (LED) products.